Innovative pharmacological form of treatment for erectile dysfunction – sildenafil in an orally dissolvable film
Authors:
Marek Broul 1 3
Authors‘ workplace:
Sexuologické oddělení, Krajská zdravotní a. s. – Masarykova nemocnice v Ústí nad Labem, o. z.
1; Urologické oddělení, Krajská zdravotní, a. s. – Nemocnice Litoměřice, o. z.
2; Fakulta zdravotnických studií UJEP v Ústí nad Labem
3
Published in:
Ces Urol 2025; 29(2): 109-113
doi:
https://doi.org/10.48095/cccu2025013
Overview
Introduction: Erectile dysfunction (ED) is a highly prevalent disorder that significantly affects the quality of life of men and their partners. Phosphodiesterase type 5 inhibitors (PDE5i), particularly sildenafil, form the first line of pharmacological treatment for ED. However, the traditional tablet form may be associated with a slower onset of action, a higher incidence of adverse effects, and reduced compliance in some patients. An innovative drug form – an orally dissolvable film containing sildenafil – has been developed to overcome these limitations. Methodology: This article summarizes the available clinical and pharmacokinetic data on the efficacy, safety, and patient preference of the new sildenafil dosage form as an orally dissolving film. Randomized controlled trials, pharmaceutical studies, and clinical experience are taken into account. Results: Sildenafil in the form of an orally dissolvable film shows comparable efficacy to the classic tablet, with a faster onset of actiondue to partial absorption through the oral mucosa. At a dose of 50 mg, the optimal therapeutic effect is achieved in most patients, which may reduce the incidence of adverse effects. The dosage form also allows for discreet use without the need for water, thereby increasing patient comfort and compliance. Conclusion: An orally dissolvable film containing sildenafil represents a modern and clinically beneficial alternative in the treatment of ED. Its use may be particularly suitable for patients who prefer a rapid onset of action, those with dysphagia, or those who prefer a discreet form of administration. Further research should verify the benefits of this form in routine clinical practice and its impact on long-term compliance and patient satisfaction.
Keywords:
erectile dysfunction – sildenafil – PDE5 inhibitors – orally dissolvable film – pharmacokinetics – pharmaceutical innovation – compliance – patient comfort – discretion
Sources
- Uroweb. EAU Guidelines – Sexual and Reproductive Health [online]. Available from: https://uroweb.org/guidelines/sexual-and-reproductive-health.
- Broul M, Kučerová P, Jozífková E et al. Treatment of thyroid disorder supported by 5-phosphodiesterase inhibitors improved erectile dysfunction in patients with hypoand hyperthyroidism. Neuro Endocrinol Lett 2024; 45(3): 180–187.
- Slíva J. Sildenafil v nové inovativní formě podání (rozpustný film). Vnitr Lek 2024; 70(1): 40–43. doi: 10.36290/vnl.2024.007.
- Yafi FA, Jenkins L, Albersen M et al. Erectile dysfunction. Nat Rev Dis Primers 2016; 2(16003). doi: 10.1038/nrdp.2016.3.
- Broul M, Štrbavý M, Skála P. Hodnocení erektilní dysfunkce po roboticky asistované radikální prostatektomii. Ces Urol 2014; 18(4): 324–333. doi: 10.48095/cccu2014046.
- Loprete L, Leuratti Ch, Frangione V et al. Pharmacokinetics of a novel sildenafil orodispersible film administered by the supralingual and the sublingual route to healthy men. Clin Drug Investig 2018; 38(8): 765–772. doi: 10.1007/s40261-018-0665-x.
- Vallance P. Sildenafil: desired and undesired effects. Hosp Med 1999; 60(3): 158–159. doi: 10.12968/hosp.1999.60.3.1057.
- De Toni L, De Rocco Ponce M, Franceschinis E et al. Sublingual administration of sildenafil oro-dispersible film: new profiles of drug tolerability and pharmacokinetics for PDE5 inhibitors. Front Pharmacol 2018; 9(59). doi: 10.3389/fphar.2018.00059.
- Radicioni M, Castiglioni Ch, Giori A et al. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional filmcoated 100 mg tablet administered to healthy male volunteers. Drug Des Devel Ther 2017; 11(11): 1183–1192. doi: 10.2147/dddt.s124034.
- WCG CenterWatch. A new sildenafil oral film in patients with erectile dysfunction [online]. Available from: https://www.centerwatch.com/ clinical-trials/listings/NCT05490680/a-new-sildenafil-oral-film-in-patients-with-erectile-dysfunction.
- Cocci A, Capece M, Cito G et al. Effectiveness and Safety of oro-dispersible sildenafil in a new film formulation for the treatment of erectile dysfunction: comparison between sildenafil 100-mg film-coated tablet and 75-mg oro-dispersible film. J Sex Med 2017; 14(12): 1606–1611. doi: 10.1016/j. jsxm.2017.10.066.
- Broul M, Hujová A, Radovnická L et al. Hyperprolaktinémie a erektilní dysfunkce. Ces Urol 2025; 29(1): 17–21. doi: 10.48095/cccu2025003.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
Most read in this issue
- Minimally invasive ureterolysis in retroperitoneal fibrosis (Ormond´s disease) – video
- Adrenocortical carcinoma – a review of current knowledge for Czech urological practice
- Editorial
- Non-invasive urinary biomarkers in the diagnosis and monitoring of bladder cancer